Over 150 New York Auctions End Today - Bid Now
Over 1350 Total Lots Up For Auction at Three Locations - NJ 04/25, MA 04/30, NJ Cleansweep 05/02

Martin M. Coyne II, Appointed Senior Business Advisor for Urovalve, Inc.

by Joan Trombetti, Writer | June 03, 2009
Martin M. Coyne II
has been appointed
Senior Business Advisor
to Urovalve, Inc.
Martin M. Coyne II has been appointed Senior Business Advisor to Urovalve, Inc.'s CEO and board of directors.

Prior to this appointment, Coyne served as Executive Vice President of Eastman Kodak Company and headed the Commercial Photography Group, which was responsible for $9 billion in sales, as well as 27,000 employees and 70% of Kodak earnings.

He has also served as Chairman of the Board of Welch Allyn, a leading manufacturer of diagnostic medical devices, and is Lead Director of Akamai Corporation, a leading Internet services company. He has served on the Executive Committee of the board of AdvaMed (Advanced Medical Technology Association), the leading industry advocacy organization for medical devices.

The president and CEO of Urovalve, Harvey D. Homan, Ph.D., said that Coyne has extensive experience in the healthcare industry at Kodak and Sterling Drug, and has held numerous management roles in sales, sales training, advertising, marketing international marketing and business development as well as general management. He said that Urovalve's directors were very enthusiastic about welcoming Coyne to the Company.

The Urovalve's Surinate® Bladder Management System is designed to remain in the urethra for up to a 30-day cycle, and is an alternative to the frequent insertions and removals of conventional urinary catheter devices-numerous times a day.

The Surinate® intraurethral valved catheter leaves no tubes or other materials outside the body, such as a urine-collection bag, and enables the individual to control voiding of urine from his bladder by using a magnetized-valve control.

The valved system is designed to greatly reduce the chance of urinary infection and allows unobtrusive operation and lifestyle normalcy. The ability to avoid infection, especially of the hospital-related type, is a huge money-saving- incentive for the healthcare system.

Urovalve expects to begin a pilot study this year of its Surinate® Bladder Management System, designed to improve the quality of life of men who suffer from acute or chronic urinary retention, an inability to empty the bladder caused by obstruction of the urethra.

Urovalve, Inc. (www.urovalve.com) is a privately held company located in the Enterprise Development Center at NJIT in Newark, New Jersey. The company develops superior medical devices to address problems associated with urinary flow and control.